As of 2025-09-15, the EV/EBITDA ratio of Cara Therapeutics Inc (CARA) is 0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CARA's latest enterprise value is -13.59 mil USD. CARA's TTM EBITDA according to its financial statements is -61.10 mil USD. Dividing these 2 quantities gives us the above CARA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.0x - 10.8x | 7.6x |
| Forward P/E multiples | 12.2x - 17.4x | 14.6x |
| Fair Price | (154.28) - (136.10) | (140.44) |
| Upside | -3000.0% - -2658.2% | -2739.9% |
| Date | EV/EBITDA |